Division of Gynecologic Oncology, Ohio State University, James Cancer Center, Columbus, OH
David M. O'Malley , Bradley J. Monk , Myong Cheol Lim , Jose Fuentes Pradera , Joseph Buscema , Michelle K. Wilson , Rocco De Vivo , Thomas J. Herzog , Flora Zagouri , Amit M. Oza , Olga N. Mikheeva , John Paul Diaz , Alla Sergeevna Lisyanskaya , Robert Morris , Ilan Bruchim , Marcia Craib , Christy Connor , Danny Shih , Keiichi Fujiwara , Rebecca Kristeleit
Background: Rucaparib provided a sustained progression-free survival benefit in patients (pts) with newly diagnosed advanced ovarian cancer after first-line treatment in the phase 3 ATHENA-MONO study (NCT03522246). We report final safety analyses (data cutoff 09 Mar 2023). Methods: Rucaparib was administered in 28-day cycles. Eligible pts were randomized 4:1 to oral rucaparib 600 mg BID (N=427) or placebo (N=111), with a treatment cap defined as 24 months. The safety population included randomized pts who received at least 1 dose of study drug (rucaparib, n=425; placebo, n=110). Results: All ATHENA-MONO pts discontinued treatment as of 24 Nov 2022 with a median treatment duration of 15 months and 35% of pts reaching the 24-month treatment cap. The median (range) relative dose intensity was 89% (30-110) for rucaparib. The rate of treatment-emergent adverse events (TEAEs), grade ≥3 TEAEs, TEAEs leading to interruption, dose reduction, or discontinuation with rucaparib remained consistent with the primary endpoint analysis with some minor changes (see Table below). Most common grade ≥3 TEAEs were anemia/decreased hemoglobin (28.7%), neutropenia/decreased neutrophils (14.6%), increased ALT/AST (10.6%), and thrombocytopenia/decreased platelets (7.3%). The most common TEAEs leading to discontinuation were anemia/decreased hemoglobin (3.5%), asthenia/fatigue (4.9%), and nausea (2.1%). Hypertension continued to be the most common TEAE observed in the placebo group (3.6%) compared with 1.6% in the rucaparib group. There were no changes in the incidence of serious adverse events or TEAEs leading to death since the primary endpoint analysis. Myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) were reported in a total of 3 pts in the rucaparib group (1 MDS during treatment [0.2%] and 1 AML and 1 MDS during long-term follow-up [0.5%]), of which the latter occurred since the primary readout. The initial MDS event that occurred during treatment, included in these incidence numbers, was considered resolved by the investigator since the initial analysis. Conclusions: Long-term maintenance treatment with rucaparib demonstrates a consistent and manageable safety profile in a broad population of pts with newly diagnosed ovarian cancer. No new safety signals were identified. Adverse events were generally manageable and led to discontinuation in a low proportion of pts. Clinical trial information: NCT03522246.
Datacut 23 Mar 2022 Rucaparib (n=425) | Datacut 23 Mar 2022 Placebo (n=110) | Datacut 09 Mar 2023 Rucaparib (n=425) | Datacut 09 Mar 2023 Placebo (n=110) | |
---|---|---|---|---|
TEAEs, % | 96.7 | 92.7 | 96.5 | 92.7 |
TEAEs ≥Grade 3, % | 60.5 | 22.7 | 60.5 | 23.6 |
TEAEs leading to discontinuation, % | 11.8 | 5.5 | 11.8 | 5.5 |
TEAEs leading to interruption, % | 60.7 | 20.0 | 60.7 | 20.0 |
TEAEs leading to dose reduction, % | 49.4 | 8.2 | 49.6 | 8.2 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Reema Anil Patel
2022 ASCO Annual Meeting
First Author: Marcia Hall
2022 ASCO Annual Meeting
First Author: Robert L. Coleman
First Author: Philipp Harter